Cargando…
Clinical Implications of Intestinal Barrier Damage in Psoriasis
BACKGROUND: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established. OBJECTIVE: To evaluate whether t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851376/ https://www.ncbi.nlm.nih.gov/pubmed/33542642 http://dx.doi.org/10.2147/JIR.S292544 |
_version_ | 1783645614072922112 |
---|---|
author | Sikora, Mariusz Stec, Albert Chrabaszcz, Magdalena Giebultowicz, Joanna Samborowska, Emilia Jazwiec, Radoslaw Dadlez, Michal Olszewska, Malgorzata Rudnicka, Lidia |
author_facet | Sikora, Mariusz Stec, Albert Chrabaszcz, Magdalena Giebultowicz, Joanna Samborowska, Emilia Jazwiec, Radoslaw Dadlez, Michal Olszewska, Malgorzata Rudnicka, Lidia |
author_sort | Sikora, Mariusz |
collection | PubMed |
description | BACKGROUND: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established. OBJECTIVE: To evaluate whether there are differences in disease activity, the severity of gastrointestinal symptoms and the blood concentration of bacterial metabolites in psoriatic patients with a normal and altered intestinal barrier. PATIENTS AND METHODS: Gut barrier integrity was assessed with the serum concentrations of claudin-3, a modulator of intestinal tight junctions and an intestinal fatty acid-binding protein, a marker of enterocyte damage. Gastrointestinal symptoms were evaluated with a validated questionnaire. The concentration of trimethylamine N-oxide (TMAO), a gut microbiota-associated metabolite, was measured with high-performance liquid chromatography. RESULTS: One hundred and fourteen patients with psoriasis were finally enrolled in the study – 68 with an altered gut barrier and 46 with a properly functioning intestinal barrier. Patients with an altered gut barrier showed a significantly higher score in the Gastrointestinal Symptom Rating Scale (3.20 vs 1.46, p<0.001). Moreover, patients with psoriasis and a disrupted intestinal barrier demonstrated a higher disease activity (PASI: 19.7 vs 10.3, p<0.001) and systemic inflammatory parameters (neutrophil-to-lymphocyte ratio: 2.86 vs 1.71, p<0.001; C-reactive protein 3.76 vs 1.92; p<0.05). The marker of bacterial translocation was significantly higher in psoriatic patients with damaged gut integrity (TMAO: 375.7±51.9 vs 119.4±27.5 ng/mL; p<0.05). CONCLUSION: The altered gut barrier in psoriasis is associated with gastrointestinal symptoms, systemic inflammatory profile and the increased blood concentration of gut microbiota-derived metabolite – TMAO. Intestinal barrier modulation represents a new promising therapeutic approach. |
format | Online Article Text |
id | pubmed-7851376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78513762021-02-03 Clinical Implications of Intestinal Barrier Damage in Psoriasis Sikora, Mariusz Stec, Albert Chrabaszcz, Magdalena Giebultowicz, Joanna Samborowska, Emilia Jazwiec, Radoslaw Dadlez, Michal Olszewska, Malgorzata Rudnicka, Lidia J Inflamm Res Original Research BACKGROUND: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established. OBJECTIVE: To evaluate whether there are differences in disease activity, the severity of gastrointestinal symptoms and the blood concentration of bacterial metabolites in psoriatic patients with a normal and altered intestinal barrier. PATIENTS AND METHODS: Gut barrier integrity was assessed with the serum concentrations of claudin-3, a modulator of intestinal tight junctions and an intestinal fatty acid-binding protein, a marker of enterocyte damage. Gastrointestinal symptoms were evaluated with a validated questionnaire. The concentration of trimethylamine N-oxide (TMAO), a gut microbiota-associated metabolite, was measured with high-performance liquid chromatography. RESULTS: One hundred and fourteen patients with psoriasis were finally enrolled in the study – 68 with an altered gut barrier and 46 with a properly functioning intestinal barrier. Patients with an altered gut barrier showed a significantly higher score in the Gastrointestinal Symptom Rating Scale (3.20 vs 1.46, p<0.001). Moreover, patients with psoriasis and a disrupted intestinal barrier demonstrated a higher disease activity (PASI: 19.7 vs 10.3, p<0.001) and systemic inflammatory parameters (neutrophil-to-lymphocyte ratio: 2.86 vs 1.71, p<0.001; C-reactive protein 3.76 vs 1.92; p<0.05). The marker of bacterial translocation was significantly higher in psoriatic patients with damaged gut integrity (TMAO: 375.7±51.9 vs 119.4±27.5 ng/mL; p<0.05). CONCLUSION: The altered gut barrier in psoriasis is associated with gastrointestinal symptoms, systemic inflammatory profile and the increased blood concentration of gut microbiota-derived metabolite – TMAO. Intestinal barrier modulation represents a new promising therapeutic approach. Dove 2021-01-27 /pmc/articles/PMC7851376/ /pubmed/33542642 http://dx.doi.org/10.2147/JIR.S292544 Text en © 2021 Sikora et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Sikora, Mariusz Stec, Albert Chrabaszcz, Magdalena Giebultowicz, Joanna Samborowska, Emilia Jazwiec, Radoslaw Dadlez, Michal Olszewska, Malgorzata Rudnicka, Lidia Clinical Implications of Intestinal Barrier Damage in Psoriasis |
title | Clinical Implications of Intestinal Barrier Damage in Psoriasis |
title_full | Clinical Implications of Intestinal Barrier Damage in Psoriasis |
title_fullStr | Clinical Implications of Intestinal Barrier Damage in Psoriasis |
title_full_unstemmed | Clinical Implications of Intestinal Barrier Damage in Psoriasis |
title_short | Clinical Implications of Intestinal Barrier Damage in Psoriasis |
title_sort | clinical implications of intestinal barrier damage in psoriasis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851376/ https://www.ncbi.nlm.nih.gov/pubmed/33542642 http://dx.doi.org/10.2147/JIR.S292544 |
work_keys_str_mv | AT sikoramariusz clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT stecalbert clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT chrabaszczmagdalena clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT giebultowiczjoanna clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT samborowskaemilia clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT jazwiecradoslaw clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT dadlezmichal clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT olszewskamalgorzata clinicalimplicationsofintestinalbarrierdamageinpsoriasis AT rudnickalidia clinicalimplicationsofintestinalbarrierdamageinpsoriasis |